SUPN 8-K 2026-11-02

SUPERNUS PHARMACEUTICALS, INC. (SUPN) 8-K dated 2026-11-02 — accession 0001104659-26-121014.

SUPERNUS PHARMACEUTICALS, INC. (SUPN) is a drug manufacturers - specialty & generic company listed on NASDAQ.

SUPERNUS PHARMACEUTICALS, INC. filed a 8-K on 2026-11-02. Accession 0001104659-26-121014.

This 8-K covers: Material agreement (Item 1.01), Acquisition or disposition (Item 2.01), New debt obligation (Item 2.03), Change to holders' rights (Item 3.03), Change in control (Item 5.01), Bylaws or fiscal year change (Item 5.03). SEC EDGAR holds the official filing and its exhibits.

Latest reported SUPN revenue for 2025-12-31 was $719.0M. Net income was -$38.5M. Revenue was up 8.6% from 2024-12-31 to 2025-12-31. SUPN currently screens at market cap $2.53B.

Not investment advice. The SUPN SEC hub lists recent forms. The stock page is the research view.